Shukra [SHUKRAPHAR] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison

Shukra Pharmaceuticals Ltd.

BSE
Loading...

Gujarat Themis Biosyn Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Shukra Pharmaceuticals Ltd. wins in 11 metrics, Gujarat Themis Biosyn Ltd. wins in 9 metrics, with 0 ties. Shukra Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Shukra Pharmaceuticals Ltd. Gujarat Themis Biosyn Ltd. Better
P/E Ratio (TTM) 770.20 73.73 Gujarat Themis Biosyn Ltd.
Price-to-Book Ratio 22.86 13.36 Gujarat Themis Biosyn Ltd.
Debt-to-Equity Ratio 5.71 27.04 Shukra Pharmaceuticals Ltd.
PEG Ratio 1.39 -17.55 Shukra Pharmaceuticals Ltd.
EV/EBITDA 34.62 52.76 Shukra Pharmaceuticals Ltd.
Profit Margin (TTM) 45.16% 29.99% Shukra Pharmaceuticals Ltd.
Operating Margin (TTM) 67.87% 40.16% Shukra Pharmaceuticals Ltd.
EBITDA Margin (TTM) 67.87% 40.16% Shukra Pharmaceuticals Ltd.
Return on Equity 15.24% 19.64% Gujarat Themis Biosyn Ltd.
Return on Assets (TTM) 11.04% 16.19% Gujarat Themis Biosyn Ltd.
Free Cash Flow (TTM) $51.75M $-251.22M Shukra Pharmaceuticals Ltd.
Dividend Yield 3.20% 0.17% Shukra Pharmaceuticals Ltd.
1-Year Return 104.99% 15.75% Shukra Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 21.46 22.23 Shukra Pharmaceuticals Ltd.
Enterprise Value $13.61B $36.09B Gujarat Themis Biosyn Ltd.
EV/Revenue Ratio 21.08 22.65 Shukra Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 81.77% 83.29% Gujarat Themis Biosyn Ltd.
Revenue per Share (TTM) $1 $15 Gujarat Themis Biosyn Ltd.
Earnings per Share (Diluted) $-0.20 $4.40 Gujarat Themis Biosyn Ltd.
Beta (Stock Volatility) 0.94 -0.17 Gujarat Themis Biosyn Ltd.

Shukra Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd. Stock Performance Analysis

Loading Price Chart...

SHUKRAPHAR
GUJTHEM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Shukra Pharmaceuticals Ltd.3.57%-2.60%-1.15%-23.64%-42.21%-44.86%
Gujarat Themis Biosyn Ltd.-0.57%-4.89%4.00%38.98%-1.40%-12.59%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Shukra Pharmaceuticals Ltd.104.99%517.94%1,925.00%2,071.74%707.82%707.82%
Gujarat Themis Biosyn Ltd.15.75%76.92%76.92%76.92%76.92%76.92%

Performance & Financial Health Analysis: Shukra Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.

MetricSHUKRAPHARGUJTHEM
Market Information
Market Cap i₹13.91B₹35.41B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i458,42579,452
90 Day Avg. Volume i341,812106,446
Last Close₹31.04₹385.10
52 Week Range₹12.97 - ₹65.26₹225.05 - ₹479.00
% from 52W High-52.44%-19.60%
All-Time High₹65.26 (Dec 19, 2025)₹479.00 (Oct 27, 2025)
% from All-Time High-52.44%-19.60%
Growth Metrics
Quarterly Revenue Growth2.45%0.10%
Quarterly Earnings Growth5.44%-0.04%
Financial Health
Profit Margin (TTM) i0.45%0.30%
Operating Margin (TTM) i0.68%0.40%
Return on Equity (TTM) i0.15%0.20%
Debt to Equity (MRQ) i5.7127.04
Cash & Liquidity
Book Value per Share (MRQ)₹1.38₹24.29
Cash per Share (MRQ)₹0.31₹0.92
Operating Cash Flow (TTM) i₹66.80M₹970.68M
Levered Free Cash Flow (TTM) i₹95.75M₹487.72M
Dividends
Last 12-Month Dividend Yield i3.20%0.17%
Last 12-Month Dividend i₹1.02₹0.67

Valuation & Enterprise Metrics Analysis: Shukra Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.

MetricSHUKRAPHAR (Apr 24, 2026)GUJTHEM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i770.2073.73
Forward P/E iN/AN/A
PEG Ratio i1.39-17.55
Price to Sales (TTM) i21.4622.23
Price to Book (MRQ) i22.8613.36
Market Capitalization
Market Capitalization i₹13.91B₹35.41B
Enterprise Value i₹13.61B₹36.09B
Enterprise Value Metrics
Enterprise to Revenue i21.0822.65
Enterprise to EBITDA i34.6252.76
Risk & Other Metrics
Beta i0.94-0.17
Book Value per Share (MRQ) i₹1.38₹24.29

Financial Statements Comparison: Shukra Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSHUKRAPHAR (2025)GUJTHEM (2025)
Revenue/Sales i325.87M1.51B
Cost of Goods Sold i81.12M318.78M
COGS % of Revenue i24.9%21.1%
Gross Profit i244.76M1.19B
Gross Margin i75.1%78.9%
Research & Development i1.66M34.37M
Operating Income (EBIT) i97.25M642.49M
Operating Margin i29.8%42.6%
EBITDA i168.63M713.04M
EBITDA Margin i51.7%47.3%
Pre-Tax Income i133.37M655.38M
Pre-Tax Income % of Revenue i40.9%43.5%
Income Tax i37.61M167.66M
Income Tax % of Revenue i11.5%11.1%
Net Income (Profit) i95.75M487.72M
Profit Margin i29.4%32.3%

Balance Sheet & Liquidity Metrics

MetricSHUKRAPHAR (2025)GUJTHEM (2025)
Cash & Equivalents i121.18M116.94M
Total Current Assets i654.27M519.73M
Total Current Assets % of Revenue i200.8%34.5%
Total Current Liabilities i172.84M205.60M
Total Current Liabilities % of Revenue i53.0%13.6%
Long-Term Debt i31.13M296.36M
Long-Term Debt % of Revenue i9.6%19.7%
Total Shareholders Equity i628.36M2.48B
Retained Earnings i143.00M2.37B
Retained Earnings % of Revenue i43.9%157.4%
Property, Plant & Equipment i193.97M411.30M

Cash Flow Statement Comparison

MetricSHUKRAPHAR (2025)GUJTHEM (2025)
Operating Cash Flow i66.80M970.68M
Operating Cash Flow % of Revenue i20.5%64.4%
Capital Expenditures i-27.43M-1.16B
Free Cash Flow i51.75M-251.22M
FCF Margin i15.9%-16.7%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSHUKRAPHARGUJTHEM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i437.88M108.97M
Float Shares i46.25M29.52M
% Held by Insiders i89.33%71.98%
% Held by Institutions i0.00%1.18%
% Held by Public i10.67%26.84%

Dividend Analysis & Yield Comparison: Shukra Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.

MetricSHUKRAPHARGUJTHEM
Last 12-Month Dividend i₹1.02₹0.67
Last 12-Month Dividend Yield i3.20%0.17%
3-Year Avg Annual Dividend i₹0.35₹0.22
3-Year Avg Dividend Yield i3.91%0.17%
3-Year Total Dividends i₹1.05₹0.67
Ex-Dividend DateSep 23, 2025Sep 04, 2025